Distinguished in Fragile X Syndrome

Andrew C. Stanfield

George Square, 
Edinburgh, SCT, GB 
Distinguished in Fragile X Syndrome
George Square, 
Edinburgh, SCT, GB 
OverviewLocationsClinical Research

Overview

Andrew Stanfield practices in Edinburgh, United Kingdom. Mr. Stanfield is rated as a Distinguished expert by MediFind in the treatment of Fragile X Syndrome. His top areas of expertise are Fragile X Syndrome, Autism Spectrum Disorder, Drug Induced Dyskinesia, and Schizophrenia.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles and participated in 1 clinical trial in the study of Fragile X Syndrome.

Gender
Male

Locations

George Square, Edinburgh, SCT, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT
Enrollment Status: Completed
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drug: ZYN002
Study Phase: Phase 3
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drug: Arbaclofen
Study Phase: Phase 2
View 1 Less Clinical Trial

46 Total Publications

Behavioural difficulties in fragile X syndrome: current pharmacological options and potential future developments.
Behavioural difficulties in fragile X syndrome: current pharmacological options and potential future developments.
Journal: Expert review of neurotherapeutics
Published: June 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Stanfield's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile